Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Healthcare-associated infection impact with bioaerosol treatment and COVID-19 mitigation measures

M.H. Ereth a,*, J. Fine b, F. Stamatas c, B. Mathew b, D. Hess c, E. Simpser b

a Mayo Clinic College of Medicine, Rochester, MN, USA
b St. Mary's Hospital for Children, Bayside, NY, USA
c SecureAire, Inc, Dunedin, FL, USA

SUMMARY

Background: The real-world impact of breathing zone air purification and coronavirus disease 2019 (COVID-19) mitigation measures on healthcare-associated infections is not well documented. Engineering solutions to treat airborne transmission of disease may yield results in controlled test chambers or single rooms, but have not been reported on hospital-wide applications, and the impact of COVID-19 mitigation measures on healthcare-associated infection rates is unknown.

Aim: To determine the impact of hospital-wide bioaerosol treatment and COVID-19 mitigation measures on clinical outcomes.

Methods: The impact of the step-wise addition of air disinfection technology and COVID-19 mitigation measures to standard multi-modal infection control on particle counts, viral and bacterial bioburden, and healthcare-associated infection rates was investigated in a 124-bed hospital (>100,000 patient-days over 30 months).

Findings and conclusion: The addition of air disinfection technology and COVID-19 mitigation measures reduced airborne ultrafine particles, altered hospital bioburden, and reduced healthcare-associated infections from 11.9 to 6.6 (per 1000 patient-days) and from 6.6 to 1.0 (per 1000 patient-days), respectively (P<0.0001, R²=0.86). No single technology, tool or procedure will eliminate healthcare-associated infections, but the addition of a ubiquitous facility-wide engineering solution at limited expense and with no alteration to patient, visitor or staff traffic or workflow patterns reduced infections by 45%. A similar impact was documented with the addition of comprehensive, restrictive, and labour- and material-intensive COVID-19 mitigation measures. To the authors’ knowledge, this is the first direct comparison between traditional infection control, an engineering solution and COVID-19 mitigation measures.

© 2021 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Bioaerosols that carry bacteria, viruses and fungi serve as transmission vehicles for diverse infections, including influenza viruses, severe acute respiratory syndrome viruses, and the novel human coronavirus (SARS-CoV-2). Sneezing, coughing,
speaking and breathing release and disperse droplets and virus particles [1,2]. The clinical consequences of bioaerosols involve complex physical and biological factors, and disinf ecting bioaerosols is difficult in any indoor air environment.

Cough- and sneeze-generating gas clouds with pathogen-bearing droplets can travel up to 8 m, and, once desiccated, the residue or droplet nuclei may stay suspended for hours [3]. Some of the smallest particles (such as viruses <30 nm in diameter) can invade a room rapidly and may be the most infectious [4,5]. Even large particles (droplets >100 μm) can be resuspended and aerosolized, and may behave like small aerosols due to the local environment [6,7]. Aerosols and droplets are subject to a person’s thermal plume, air currents produced by human traffic, door movements, electrostatic forces, Brownian motion and convective flows [8-11]. The constant and turbulent factors within a typical hospital increase broader dissemination, and extend the settling time of these disease-carrying pathogens [12].

There is now evidence to warrant engineering controls that target airborne transmission as part of an overall strategy to limit indoor infectious risk [13]. Components of these strategies include air disinfection, ventilation, enhanced particle filtration and avoidance of recirculation. Traditional infection control strategies such as education, handwashing, surface cleaning and isolation measures with personal protective equipment (PPE) were primarily developed for large droplet and surface contamination. Such strategies have limited ability to combat airborne pathogens, especially those suspended continuously within 0.3-m radius of a nose and mouth, commonly described as the ‘breathing zone’. Given the human and environmental factors that constantly move aerosols and resuspend droplets, the concept of clearing a room of all suspended or airborne pathogens is not as simple as increasing air flow and installing a finer filter [11].

Current technologies that help clean a ducted air stream include high-efficiency particulate air (HEPA) filtration, heating ventilation and air-conditioning modifications, ultraviolet (UV) radiation, and various intraduct oxidizing or ionizing technologies [13]. Benefits attributed to these technologies are often cited from tightly controlled experiments within test chambers, but these are not real-world settings. Each of these technologies may provide benefit within environmental chambers, but few have the capacity to continuously counter the numerous and constant infectious and environmental perturbations of a real-world setting. Ideal air disinfection would be easily applied to all areas so that all breathing zone air would be treated, and would result in reduced particulate pollution, reduced pathogen contamination, reduced disease transmission and, finally, a reduction in real-world clinical infections.

The ACTIVE Particle Control (APC) system (SecureAire, LLC, Dunedin, FL, USA) has been shown to reduce fine and ultrafine airborne particles and pathogens in live operating rooms, reduce bacterial contamination in active hospital compounding pharmacies, and rapidly inactivate or kill the highly resistant anthrax surrogate (Bacillus subtilis) [14,15]. This novel technology works by local electromagnetic field manipulation [controlled ionization, enhanced polarization and controlled particle transport (direction and velocity)]. These forces condition the microparticles (microscopic particles 1–1000 μm) and pathogens within a space, so they continuously initiate millions of particle–particle (ionization) and particle–molecular (polarization) collisions. These collisions lead to immediate and permanent ionically driven aggregations of fine and ultrafine particles and pathogens into larger particles. With the larger aggregates attaining a critical mass, their transport becomes controlled by air flow and they can be carried by air currents to the particle collector (Figure 1).

This study aimed to determine the impact of adding a hospital-wide APC system and coronavirus disease (COVID-19) mitigation measures to a multi-modal infection control strategy on particle and pathogen counts, respiratory viral illnesses and healthcare-associated infections (HAIs).

![Figure 1. Mechanism of action of the ACTIVE Particle Control system. Particulate pollutants, viruses, bacteria and allergens enter the conditioning phase and exit with a net-neutral charge. The technology-accelerated collisions result in particle agglomeration. The larger coagulated particles and their increased mass are subject to air currents that deliver the same to the collector media. Once collected, the highly defined high voltage field induces oxidative stress killing or inactivates any biological material.](image-url)
Methods

Facility

This work was conducted at St. Mary’s Hospital for Children in Bayside, Queens, NY, USA. St. Mary’s Hospital is a 124-bed paediatric post-acute care facility that provides for children with special healthcare needs and medically complex conditions. Multi-disciplinary teams of paediatric specialists provide care at St. Mary’s Hospital.

Standard infection control programme

The comprehensive infection control programme of St. Mary’s Hospital operates daily with ongoing and concurrent multi-modal processes to optimize the safety of patients, families, personnel, visitors and the environment. The programme reports process and outcome surveillance monthly. Key components of the standard programme include hand-washing promotions and signage, infection monitoring, facility antibiogram surveillance, antibiotic stewardship, transmission-based precaution modalities, PPE usage, and scheduled cleaning and disinfection procedures. Automated hand sanitizing surveillance using Bluetooth technology captures the compliance of hand hygiene upon entry or exit from the residents’ rooms, and from bed-to-bed encounters, and documents the technique and duration of hand hygiene for each staff member. Terminal cleaning of all surfaces with disinfectant is carried out upon patient room changes, and portable UV disinfection is conducted in every patient room upon patient discharge and every 5–6 weeks for routine resident room cleaning and in general common areas (Figure 2).

APC intervention

The APC system was added to the standard infection control programme in February 2019. Three commercial-sized roof-top components were added to each of the air-handling units bringing the solution to all common areas, all patient rooms, and all staff and treatment rooms. The APC system has been maintained and in operation since installation. The only hospital/patient care area that is not part of this continuous air-disinfection treatment was a single newly remodelled area (Figure 3). No data or results from this patient care unit were included in this study.

COVID-19 mitigation measures

Comprehensive COVID-19 mitigation measures were deployed in late February 2020 and included restricted visitation, screening upon entry, restrictions on volunteers and students, discontinued outpatient services, and a facility-wide comprehensive hand hygiene programme. Use of an N95 respirator mask, or face mask and visor or shield, during aerosol-generating procedures, and universal masking at other times were required (Figure 2).

Figure 2. Progressive infection control methods. Standard infection control procedures were in place in 2018. ACTIVE Particle Control technology was implemented in late February 2019, and comprehensive coronavirus disease 2019 (COVID-19) restriction and mitigation measures were implemented in late February 2020.
Measurements and outcomes

Infection control personnel conducted air quality testing for ultrafine particles (>0.35 μm) and completed air sampling for bacteria and fungi before and after installation of the APC system. Particle counts were determined using a laser-based particle counter (National Institute of Standards and Technology specifications for measuring particles >0.35 μm and >2.5 μm). Engineering control records including ventilation filter rating, humidity and temperature were documented by building engineers. Data sources included the electronic medical record, laboratory result record and hospital census records. Bacterial, fungal, respiratory viral pathogens, total pathogens and HAIs from all sources were documented continuously by infection control personnel. The predominant infectious aetiology and species isolates were documented, and total infections and infections per 1000 patient-days were determined. Next, comparisons were made between the results before and after the addition of the APC system, and after the addition of COVID-19 mitigation measures (Table I).

Statistical analysis

The mean, median and interquartile ranges were determined for particle counts, bacterial and fungal cultures, respiratory viral illness and HAIs. Comparisons were made between laboratory and clinical outcomes with the standard infection control programme, after the addition of the APC system, and after the addition of COVID-19 mitigation measures. Comparisons between these three groups were conducted using t-tests, analysis of variance, pairwise Bonferroni multiple comparisons and $R^2$ analyses. $P<0.05$ was considered to indicate statistical significance ($<0.017$ for Bonferroni correction).

Results

Patient population and characteristics

The study was conducted over 30 months with over 100,000 patient-days. The average monthly census and general diagnoses on admission did not vary significantly between any of the intervention groups. Patient, facility and microbial characteristics are summarized in Table I.

Study interval and timeline

Three consecutive years were studied. Outcomes from January and February in 2019 and 2020 would have reflected mixed or partially applied APC and COVID-19 procedures, and were thus excluded. Calendar months were also chosen in order to eliminate the possible impact of seasonal variation in allergens and influenza illness (Table I and Figure 2). Regular infection control procedure monitoring for 2018, 2019 and 2020 revealed very high and comparable rates of influenza immunization, handwashing, surface disinfection, droplet and aerosol isolation, and education measures.

Particle counts and hospital bioburden

Mean airborne particle counts (>0.35 μm/ft³) were reduced by 12–55% (mean 29%) after installation of the APC system ($P<0.01$) (Figure S1, see online supplementary material). Following installation of the APC system, few-to-no Gram-negative species were cultured, reflecting a shift in the facility-wide bioburden. None of the fungal isolates were pathogenic after installation of the APC system, as all were environmental species commonly found in households and garden areas. In the first 3 months after installation of the APC system, the respiratory viral illness rate was reduced by >90% ($P<0.001$). This

Figure 3. Roof-top placement of ACTIVE Particle Control units. ACTIVE Particle Control devices were placed within roof-top air-handling units. The entire complex is covered, with the exception of one patient unit (identified in orange).
varied throughout the 10-month study period and, while the mean respiratory viral illness rate did increase somewhat, it remained lower than in previous years and thus was reduced first by the APC system and second by the COVID-19 mitigation measures (Figure S2, see online supplementary material).

**Healthcare-associated infections**

Following implementation of the APC system, HAIs were reduced by 45% from an average of 11.9/1,000 patient-days for the standard infection control period to an average of 6.6/1000 patient-days ($P < 0.0001$). The implementation of comprehensive COVID-19 mitigation measures in late February 2020 reduced all HAIs by another 47% to 1.0/1000 patient-days ($P < 0.0001$) (Table I and Figure 4). The model analysis revealed an $R^2$ value of 0.86 (approximately 86% of the variation in the mean infection rates was accounted for by each mitigation measure). The COVID-19 mitigation measures, including community restrictions, were associated with a decline in all respiratory viral illnesses by another 72% beyond the significant impact of the APC system. The addition of the APC system was also associated with a 63% reduction in wound infections, which did not decline further with COVID-19 mitigation measures. Implementing air disinfection technology was associated with an 89% reduction in tracheitis, but did not improve further with COVID-19 mitigation measures. The incidence of *Clostridoides difficile* infections did not change after the addition of the APC system, but did decline 90% after the implementation of COVID-19 mitigation measures.

**Discussion**

Application of the APC system as an adjunct air disinfection method was associated with significantly reduced HAIs, bacterial and fungal contamination, respiratory viral pathogens and airborne particles. Further reductions in respiratory and

### Table I

Hospital characteristics and healthcare-associated infections

| Hospital characteristics | Standard IC Mar—Dec 2018 | Standard IC + APC system Mar—Dec 2019 | Standard IC + APC system + COVID-19 mitigation Mar—Dec 2020 |
|--------------------------|---------------------------|----------------------------------------|----------------------------------------------------------|
| **Hospital characteristics** |                           |                                        |                                                          |
| Months                   | 10                        | 10                                     | 10                                                       |
| Patient-days             | 31,213                    | 36,309                                 | 37,377                                                   |
| Filter MERV rating       | MERV-8 Pre                | MERV-15 Post                           | MERV-15 Post                                             |
| Average indoor relative humidity (%) | 38–42                   | 38–42                                  | 38–42                                                   |
| Average indoor temperature (°F) | 70–72                   | 70–72                                  | 70–72                                                   |
| Most common bacterial culture results | *Pseudomonas aeruginosa* | *Pseudomonas aeruginosa*              | *Pseudomonas aeruginosa*                                 |
| Most common respiratory viral pathogens | Enterovirus              | Enterovirus                            | Enterovirus                                             |
| **Healthcare-associated infections** (/1000 patient-days) |                           |                                        |                                                          |
| Mean (95% CI)            | 11.91 (10.67–13.15)       | 6.71 (5.47–7.95)                       | 1.03 (0.00–2.27)                                        |
| Median (IQR)             | 11.55 (11.00–13.00)       | 6.00 (5.10–8.10)                       | 0.95 (0.80–1.30)                                        |
| Range                    | 9.10–14.60               | 1.60–11.60                             | 0.30–2.10                                               |
| Analysis of variance modelb |                          |                                        |                                                          |
| Mean difference (95% CI) | −5.20 (−7.32 to −3.08)   | −10.88 (−13.00 to −8.76)              | −5.68 (−7.80 to −3.56)                                  |
| $P$-value                | $P<0.0001$                | $P<0.0001$                             | $P<0.0001$                                              |
| Overall $P$-value        |                           |                                        |                                                          |
| Model $R^2$ value        | 0.86                      |                                        |                                                          |

M.E. Ereth et al. / Journal of Hospital Infection 116 (2021) 69–77

$^a$ Pairwise Bonferroni multiple comparisons significance level would be compared with 0.017 (rather than 0.05).
total viral pathogens and HAIs were seen with the addition of comprehensive COVID-19 restriction and mitigation measures.

**APC system effectively clears airborne particles and pathogens**

The smallest of airborne pathogens, which are likely the most pathogenic, are the most difficult to capture by traditional filtering methods. APC technology treats and captures all particles equally, including volatile organic compounds, viruses, spores, bacteria, smoke, pollen and other aerosolized allergens [14]. Unlike filters, this solution is agnostic to bioaerosol character or size, and is therefore effective on all particles and pathogens (Figure 1). The technology operates continuously and responds rapidly to challenges introduced to a ventilated space by human activity. The behaviour of all particles (pollutants, aerosolized or airborne viruses and bacteria, pollen, etc.) is guided principally by physical laws and, to a lesser degree, by chemical and biological influences. It is the mass and spatial characteristics of these ultrafine particles (including viruses and bacteria) that keep them suspended for long periods of time, allowing for wide dispersion and diffusion. The APC system imparts both positive and negative charges, in a controlled manner utilizing Gauss’s Law (Maxwell’s first equation), on individual particles and pathogens. The technology hardware, firmware and software methodically control the electronic forces applied to fine and ultrafine particles.

The mechanism of the clinical impact of the APC system is multi-fold. First, by significantly reducing the resident time of pathogens within a hospital room or common area, the chance of adequate inoculum to infect a subject is significantly reduced. Second, pathogens and large droplets that have previously settled on surfaces and are resuspended by human activity become susceptible to APC treatment. Lastly, the technology responds rapidly and effectively to new pathogen challenges generated by coughs, sneezes or other human activity.

**Limitations of methods and results**

The single greatest limitation of this study is also its greatest strength. It was conducted in a real-world live hospital with many uncontrolled variables. As such, it is difficult to demonstrate a direct cause and effect between the intervention and a specific outcome for a specific patient. Conversely, the greatest strength of this work is that it was conducted in a live paediatric facility with a diverse patient population with varied co-morbidities, and with patients, clinicians, caregivers and family coming and going 24/7. All standard infection control procedures, processes and personnel remained consistent throughout the study, as did the patient load and general clinical characteristics of the patient population. With the COVID-19 pandemic, additional comprehensive restrictions and mitigation procedures were added. Another concern may be that airborne particles and pathogens were sampled periodically but not continuously. Viral cultures were collected from symptomatic patients, and laser-based particle counters that are an excellent surrogate for pathogen load, especially when measured at 0.4 mm, were used [16]. Critics may insist that such a result cannot be attributed to a single intervention. There are numerous examples of therapies or, in this case, an engineering solution providing synergistic benefits. The APC system was added with the express purpose of providing hospital-wide air disinfection. The study was conducted entirely by internal personnel, internal sample and laboratory culture procedures, internal data and analysis, and without outside funding or influence. The results speak for themselves in that the interventions overcame all confounding patient and facility variables.

**Aerosolized pathogens generated by normal breathing may be the most dangerous**

Healthy and influenza-infected subjects exhale up to 10,000 particles per litre during tidal breathing, with the majority...
being <0.3 μm in diameter [17–19]. Normal tidal volume exhalations, sneezes and coughs contain short-range semi-ballistic emissions that disperse quickly [20]. Most exhaled pathogens are carried in fine particles (0.7–1.0 μm) [21]. In one study, 90% of influenza viral RNA was found in exhaled particles <1.0 μm, with those same fine particles carrying eight to nine times more viral copies compared with larger droplets. Lastly, pathogens and aerosols can remain suspended in the air for long periods of time [22], with the smallest pathogens remaining resident for the longest [9,33].

**Traditional air purification technology**

Traditional air filtration is effective at removing large particulates such as pollen, mould and animal dander from the air, yet there are limitations. Viable bioaerosols such as bacteria, viruses and fungi can be demonstrated on filter media for up to 10 h after aerosolization. In less than 48 h after installation, 30% of filter media from commercial air-handling units have been contaminated with viable picornavirus, coronaviruses and parainfluenza viruses [24].

Air purification technology, such as HEPA, bipolar ionizers, photo electrochemical oxidation and UV light, can be beneficial but has significant limitations. HEPA filters effectively remove contaminants once presented to the filter matrix. However, as discussed previously, moving ultrafine particles and pathogens that are indefinitely suspended to the filter remains a limitation. Viruses are approximately 100 times smaller than bacteria, and typically range from 0.004 to 0.1 μm in size. This means that even the most efficient air filters would struggle to purge a virus from the air. It has also been demonstrated that mengovirus can pass through filters commonly used in air-handling units, and remains infectious upstream and downstream of the filter for long periods after aerosolization [25]. Many bipolar air purifiers use uncontrolled ionization to bind particles, causing pathogens to stick to surfaces within a given space. Recently, the generation of noxious chemical by-products and ozone from bipolar ionization devices has been documented, and the technology has been criticized [26,27]. The APC system distinguishes itself from bipolar ionization in that it does not create an electronic corona, nor does it generate chemical reactions or ozone [28]. The photo electrochemical oxidation solution can react with some pollutants to generate dangerous by-products such as formaldehyde, nitrogen dioxide and carbon monoxide. Disinfection with UV light is time- and intensity-dependent, and is highly effective on flat surfaces yet does not kill airborne pathogens, and the benefits of UV disinfection only persist until human traffic re-enters and contaminates the treated space [29].

Particle size is the most important determinant of aerosol behaviour. Particles ≤5 μm in size can remain airborne indefinitely under most indoor conditions [9,30,31]. Immediately respirable aerosols from exhaled breath and coughs are generally fine (<2.5 μm) or ultrafine (<0.1 μm), and appear to carry the largest inoculum of viruses; as such, they are the most infectious [32].

**Healthcare-associated infections**

HAs are the most common complication of health care and are one of the top 10 leading causes of death [33]. Controlling airborne transmission of infection is not simple or easy. Antiseptic techniques, wearing PPE and infection prevention procedures are critical. Also critical is deploying engineering solutions that are proven to reduce patient complications [34]. Both the APC system and the COVID-19 mitigation measures resulted in similar reductions in the HAI rate. The first solution required a single capital outlay and runs continuously, and never interrupts staff work flow or inconveniences patients or family members. The second solution is time-, equipment-, material- and labour-intensive, and causes significant interruptions to staff work flow.

**Engineering solutions applied across all spaces**

There is now strong evidence to warrant engineering solutions that target immediately respirable particles (viral laden aerosols) in the 0.7–1.0-μm range [8]. This is even more important as the evidence base for the 1–2-m rule of spatial separation is inconclusive, and it is known that aerosols can travel horizontally for up to 9 m [35–37]. Effective engineering solutions must harness the laws of physics to enable clearance of particle pollutants and pathogens from the ventilated space. The repeated assumption is that all airborne pathogens, regardless of size, behave the same and are susceptible to air currents. The incorrect assumption is that air flow alone can transport pathogens to the filter or device, where they are completely cleared from the air stream. These assumptions counter the laws of physics which dictate that ultrafine particles are more susceptible to electrostatic forces than gravity or air currents [9]. Specialized ventilation, such as positive and negative pressurized rooms and high air exchanges per hour, may help to prevent the spread of disease, but this is expensive to install, has high energy costs, and does not fully address the human traffic factor in aerosol dispersion [38].

**Airborne transmission of non-airborne infections?**

Over the past 18 months, the transmission of disease has been actively studied, and there is greater awareness of the complexity of coughs and sneezes and the aerosols they produce. Understanding of the impact of human activities on indoor air currents, resuspension of settled droplets, unintended consequences of air currents in operating rooms, and broader concepts of pathogen migration has improved [6,7,11]. However, little is actually known about the relative contribution of disease transmission by contact, fomite, droplet or aerosol routes [39]. The work presented here found that the APC system was associated with reductions in HAs, wound infection, tracheitis and respiratory viral infections. Can air disinfection technology impact contact, fomite and droplet routes of disease transmission? Real-world evidence and three-dimensional modelling have demonstrated that air currents clearly alter dispersal of bacteria in operating rooms [6,7,11]. Non-respiratory fomites in virally infected animals are readily aerosolized and airborne [40]. Also, genetically traced and aerosolized *Escherichia coli* has been demonstrated in adjacent homes, demonstrating airborne transmission between built environments [41]. Certainly, some human activities and/or engineering solutions may impart airborne transmissibility to traditionally non-airborne diseases, but what activity, to what degree, and what is the clinical outcome? Given this, it is certainly possible that a treatment targeting airborne disease
could impact non-airborne disease. The question is simple, but the answers are complex, elusive and warrant further investigation.

In conclusion, in a real-world hospital setting with over 100,000 patient-days over 30 months, there was a significant reduction in HAIs (including respiratory viral pathogens) when an engineering solution (APC system) was added to the standard infection control procedures. Even further reductions were achieved by comprehensive COVID-19 mitigation measures. Effectively disinfecting all breathing zone air may be especially helpful in reducing airborne disease transmission and acquired infections in hospitals or other institutional settings.

Author contributions

Dr. Simpser, Ms. Mathew and Ms. Fine were responsible for infection control policy development and supervision. Ms. Fine was responsible for implementation of infection control policies, staff education, surveillance, and infection control procedures and processes. She was also responsible for sample collection/coordination and data collection and analysis/visualization. Ms Fine and Mr. Stamatos assisted with particle count methods and manuscript preparation. Mr. Hess provided technical guidance, data review and manuscript preparation. Dr. Ereth was responsible for additional data visualization and writing the manuscript.

Acknowledgements

The authors wish to thank Ms. Kimberly Sankey for assistance with manuscript preparation, Mr. William Scott Harmsen for statistical analysis, and Dr. William L. Lanier for review and guidance.

Conflict of interest statement

Dr. Ereth is Chief Medical Officer of, and an investor in, SecureAire, Inc. Mr. Stamatos is Chief Executive Officer of, and an investor in, SecureAire, Inc. Mr. Hess is Chief Technical Officer of, and an investor in, SecureAire, Inc. Dr. Simpser, Ms. Fine and Ms. Mathew report no conflicts of interest.

Funding sources

All funding for this work was provided by St. Mary’s Hospital for Children. The entire cost of purchase, installation and service of the APC system, all laboratory and personnel costs, and the cost of data collection and analysis was funded by St. Mary’s Hospital for Children. The particle counter and graphic assistance were provided by SecureAire, Inc.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhin.2021.07.006.

References

[1] Bischoff WE, Swett K, Leng I, Peters TR. Exposure to influenza virus aerosols during routine patient care. J Infect Dis 2013;207:1037–46.

[2] Fabian P, McDevitt JJ, DeHaan WH, Fung RO, Cowling BJ, Chan KH, et al. Influenza virus in human exhaled breath: an observational study. PLoS One 2008;3:e2691.

[3] Bourouiba L. Turbulent gas clouds and respiratory pathogen emissions: potential implications for reducing transmission of COVID-19. JAMA 2020;323:1837–8.

[4] Morawska L, Johnson GR, Ristovski ZD, Hargreaves M, Mengersen K, Corbett S, et al. Size distribution and sites of origin of droplets expelled from the human respiratory tract during expiratory activities. J Aerosol Sci 2009;40:256–69.

[5] Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. Lancet Respir Med 2020;8:914–24.

[6] Rezapoor M, Alvand A, Jakec E, Paziuk T, Maltenfort MG, Parvizi J. Operating room traffic increases aerosolized particles and compromises the air quality: a simulated study. J Arthroplasty 2018;33:851–5.

[7] Bhattacharya A, Pantelic J, Ghahramani A, Mousavi ES. Three-dimensional analysis of the effect of human movement on indoor airflow patterns. Indoor Air 2021;31:587–601.

[8] Tang JW, Bahnfleth WP, Bluyssen PM, Buonanno G, Jimenez JL, Kumitski J, et al. Dismantling myths on the airborne transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Hosp Infect 2021;110:89–96.

[9] Li C, Wang H, Yu CW, Xie D. Diffusion characteristics of the industrial submicron particle under Brownian motion and turbulent diffusion. Indoor Built Environ 2021. https://doi.org/10.1177/1420326X21991055.

[10] Wagner JA, Greetley DG, Gormley TC, Markel TA. Comparison of operating room air distribution systems using the environmental quality indicator method of dynamic simulated surgical procedures. Am J Infect Control 2019;47:e1–6.

[11] Agodi A, Auxilia F, Barchitta M, Cristina ML, D’Alessandro D, Mura I, et al. Operating theatre ventilation systems and microbial air contamination in total joint replacement surgery: results of the GISIO-ISchIA study. J Hosp Infect 2015;90:213–9.

[12] Birgand G, Peiffer-Smadja N, Fournier S, Kenneis S, Lescure FX, Lucet JC. Assessment of air contamination by SARS-CoV-2 in hospital settings. JAMA NetworkOpen 2020;3:e2033232.

[13] Morawska L, Tang JW, Bahnfleth W, Bluyssen P, Boerstra A, Buonanno G, et al. How can airborne transmission of COVID-19 indoors be minimised? Environ Int 2020;142:105832.

[14] Ereth MH, Hess DH, Driscoll A, Hernandez M, Stamatos F. Particle control reduces fine and ultrafine particles greater than HEPA filtration in live operating rooms and kills biologic warfare surrogate. Am J Infect Control 2020;48:777–80.

[15] SecureAire, LLC. ACTIVE Particle Control technology and USP 800 pharmaceutical compounding. Dunedin, FL: SecureAire; 2018. Available at: https://secureaire.com/markets/healthcare/white-papers/ [last accessed July 2021].

[16] Raval JS, Koch E, Donnenberg AD. Real-time monitoring of non-viable airborne particles correlates with airborne colonies and represents an acceptable surrogate for daily assessment of cell-processing cleanroom performance. Cytotherapy 2012;14:1144–50.

[17] WHO. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations. Geneva: World Health Organization; 2020.

[18] CDC. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. Atlanta, GA: US Centers for Disease Control and Prevention; 2020.

[19] Edwards DA, Man JC, Brand P, Kastra JP, Sommerer K, Stone HA, et al. Inhaling to mitigate exhaled bioaerosols. Proc Natl Acad Sci USA 2004;101:17383–8.

[20] Bourouiba L, Dehandschoevercker E, Bush JW. Violent expiratory events: on coughing and sneezing. J Fluid Mech 2014;745:537–63.
[21] Bake B, Larsson P, Ljungkvist G, Ljungström E, Olin AC. Exhaled particles and small airways. Respir Res 2019;20:8.
[22] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564–7.
[23] Lindsley WG, King WP, Thewlis RE, Reynolds JS, Panday K, Cao G, et al. Dispersion and exposure to a cough-generated aerosol in a simulated medical examination room. J Occup Environ Hyg 2012;9:681–90.
[24] Myatt TA, Johnston SL, Zuo Z, Wand M, Kebadze T, Rudnick S, et al. Detection of airborne rhinovirus and its relation to outdoor air supply in office environments. Am J Respir Crit Care Med 2004;169:1187–90.
[25] Bandaly V, Joubert A, Le Cann P, Andres Y. The fate of mengovirus on fiberglass filter of air handling units. Food Environ Virol 2017;9:464–72.
[26] Zeng Y, Manwatkar P, Laguerre A, et al. Evaluating a commercially available in-duct bipolar ionization device for pollutant removal and potential byproduct formation. Build Environ 2021;195.
[27] Zaatari M, Harmon M. Open letter to address the use of electronic air cleaning equipment in buildings. medium.com. 2021; Available at: https://medium.com/open-letter-to-address-the-use-of-electronic-air/no-to-ionizers-plasma-uvpc-bc1570b2fb9b [last accessed August 2021].
[28] Intertek. SecureAire LLC ozone test report. Cortland, NY: Intertek; 2020.
[29] Ong SWX, Tan YK, Chia PY, Lee TH, Ng OT, Wong MSY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 2020;323:1610–2.
[30] Wells WF. Aerodynamics of droplet nuclei. Airborne contagion and air hygiene: an ecological study of droplet infections. Cambridge: Harvard University Press; 1955. p. 13–9.
[31] Brown JH, Cook KM, Ney FG, Hatch T. Influence of particle size upon the retention of particulate matter in the human lung. Am J Public Health Nations Health 1950;40:450–80.
[32] Scheuch G. Breathing is enough: for the spread of influenza virus and SARS-CoV-2 by breathing only. J Aerosol Med Pulm Drug Deliv 2020;33:230–4.
[33] Agency for Healthcare Research and Quality. Healthcare-associated infections. Rockville, MD: Agency for Healthcare Research and Quality; 2018. Available at: https://www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/resources/hais/index.html [last accessed July 2021].
[34] van Rijn C, Somsen GA, Hofstra L, Dahhan G, Gem RA, Kooij S, et al. Reducing aerosol transmission of SARS-CoV-2 in hospital elevators. Indoor Air 2020;30:1065–6.
[35] Bahl P, Doolan C, de Silva C, Chughtai AA, Bourouiba L, MacIntyre CR. Airborne or droplet precautions for health workers treating COVID-19? J Infect Dis 2020; https://10.1093/infdis/jiaa189.
[36] Jones NR, Qureshi ZU, Temple RJ, Larwood JPJ, Greenhalgh T, Bourouiba L. Two metres or one: what is the evidence for physical distancing in COVID-19? BMJ 2020;370:m3223.
[37] Bazant MZ, Bush JWM. A guideline to limit indoor airborne transmission of COVID-19. Proc Natl Acad Sci USA 2021;118:17.
[38] Santarpia JL, Rivera DN, Herrera VL, Morwitzer MJ, Creager HM, Santarpia GW, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep 2020;10:12732.
[39] Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol 2021. https://doi.org/10.1038/s41579-021-00535-6:1-18.
[40] Asadi S, Gaaloul Ben Hnia N, Barre RS, Wexler AS, Ristenpart WD, Bouvier NM. Influenza A virus is transmissible via aerosolized fomites. Nat Commun 2020;11:4062.
[41] Li Z, Wang H, Zheng W, Li Z, Wang H, Zheng W, et al. A tracing method of airborne bacteria transmission across built environments. Build Environ 2019;164:106335.